Neurotranslation to address the attrition problem in neuroscience drug discovery

Value of the Information & Strength of the Argument

The talk provides valuable insights into the challenges of neuroscience drug development and presents a compelling argument for using human genetics and translational medicine to improve success rates. The speaker supports his claims with specific examples, such as the development of the osteoporosis drug romosozumab from a rare genetic mutation, and cites industry-wide statistics. However, the argumentation is largely based on his own company’s experience and may not be universally applicable. The lack of detailed methodological explanations for the presented metrics limits the ability to fully assess the robustness of the claims.

Scientific Rigor, Source Quality, Title Accuracy

The talk references several published studies, including a 2004 paper in Nature Reviews Drug Discovery co-authored by the speaker, and data from KMR and Tufts. The sources are credible, but the talk does not provide full citations or URLs. The title accurately reflects the content, focusing on translational approaches to reduce attrition. The speaker’s expertise and the use of industry data lend credibility, but the presentation is an expert opinion rather than a systematic review.

The title accurately reflects the content, focusing on translational approaches to reduce attrition in neuroscience drug development.

8/10

The speaker is a highly experienced pharmaceutical executive with a strong scientific background, and the talk references published studies and data. However, it is primarily an expert opinion with some data presented without full methodological detail.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 01:00Introduction: UCB's commitment to neuroscience research despite industry pullout.
• 03:00Attrition problem: 1 in 11 molecules succeeds, CNS even lower.
• 05:00Phase 3 failures: 67% for CNS, mainly due to lack of efficacy.
• 07:00Use of human genetics: example of sclerostin antibody from rare genetic disease.
• 09:00Qatari population study: high homozygosity, rare variants.
• 11:00Learn and confirm paradigm: proof of concept with small patient numbers.
• 13:00Use of biomarkers and imaging for target engagement.
• 15:00Improved metrics: 25% phase 3 failure vs 67% industry, shorter timelines.

• Kola & Landis (2004) Nature Reviews Drug Discovery — Paper on attrition in pharmaceutical industry.
• KMR data on success rates — Industry-wide success rates in drug development.
• Tufts School of Medicine cost analysis — Fully-loaded cost to bring a medicine to market.
• New England Journal of Medicine publication on sclerostin antibody — Phase 3 results for osteoporosis drug.
• Nature Communications paper on epilepsy genetics — Identification of gene for epilepsy.

• Kola & Landis (2004) — Attrition problem in pharma.
• Tufts CSDD data — Cost and success rates.

• Some may argue that genetic approaches are not yet proven — The speaker's emphasis on rare variants is promising but not universally accepted as a solution.